Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids

V. Kiri, G. Visick, C. Chigbo, G. Hagan, H. Muellerova, K. Davis (Greenford, Middlesex, Cheshunt, Hertfordshire, United Kingdom; Research Triangle Park, NC, United States Of America)

Source: Annual Congress 2007 - Epidemiology of COPD
Session: Epidemiology of COPD
Session type: Thematic Poster Session
Number: 3677
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Kiri, G. Visick, C. Chigbo, G. Hagan, H. Muellerova, K. Davis (Greenford, Middlesex, Cheshunt, Hertfordshire, United Kingdom; Research Triangle Park, NC, United States Of America). Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids. Eur Respir J 2007; 30: Suppl. 51, 3677

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021


Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011



Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010



Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia
Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD
Year: 2010


Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?
Source: Eur Respir J 2011; 37: 1-3
Year: 2011


Inhaled corticosteroids and pneumonia mortality in COPD patients
Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019
Year: 2019



Inhaled corticosteroids and pneumonia mortality in COPD patients
Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019
Year: 2019



Inhaled corticosteroid related pneumonia in real world among the patients with asthma and COPD
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009



Risks of pneumonia in asthmatic patients taking inhaled corticosteroids
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004



Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006


Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD
Source: Annual Congress 2012 - COPD: risk factors, biomarkers and diagnosis
Year: 2012



Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016

Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003



Are inhaled corticosteroids increasing the “load” for some patients with COPD?
Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017
Year: 2017



Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations
Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Year: 2018